Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.'s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons. In his new role, Dr. Liu is no longer a Section 16 or executive officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.54 USD | +0.22% | +11.71% | +37.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.72% | 1.85B | |
+31.61% | 49.46B | |
+2.14% | 42.58B | |
+49.11% | 42.49B | |
-5.26% | 29.09B | |
+12.83% | 26.61B | |
-23.42% | 18.64B | |
+8.20% | 13.16B | |
+31.32% | 12.55B | |
+24.10% | 12.1B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor